(Q30391041)

21 June 2017

title

Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009/10. (English)

1 reference

21 June 2017

0 references

Alenka Kraigher

1

1 reference

21 June 2017

Veronika Ucakar

series ordinal

2

1 reference

21 June 2017

language of work or name

English

0 references

publication date

18 June 2010

1 reference

21 June 2017

1 reference

21 June 2017

volume

28

1 reference

21 June 2017

issue

33

1 reference

21 June 2017

page(s)

5467-5472

1 reference

Progress with human H5N1 vaccines: a perspective from industry.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

What should an ideal vaccine postlicensure safety system be?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Controversies in vaccine mandates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Vaccination, squalene and anti-squalene antibodies: facts or fiction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

Vaccines and Guillain-Barré syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.066

10.1016/J.VACCINE.2010.05.066

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference